Experimental drug flotetuzumab tested in just 3 patients for relapsed AML
NCT ID NCT05506956
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study tested the safety of a drug called flotetuzumab in 3 adults with acute myeloid leukemia (AML) that had returned after a stem cell transplant. The drug targets a protein on leukemia cells and was given as a continuous infusion. The main goal was to find a safe dose, not to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
flotetuzumab
What this could lead to
If it works, this could point toward a treatment for AML that has relapsed after transplant.
What could go wrong
This is a very early, tiny phase 1 trial with only 3 participants. It focuses on safety, not effectiveness, and may not lead to a proven treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States